SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis.

scientific article

SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/CAS.13515
P932PMC publication ID5891175
P698PubMed publication ID29369502

P50authorQing ChangQ87613419
P2093author name stringMing Zhang
Yan Liu
Jing Zhang
Min Ding
Na Li
Tao Jiang
Chen Zheng
Xiao-Yu Wu
Yong-Xiao Li
Yu-Feng Wu
Zhen-Wei Yu
Li-Wei Shao
Dan-Feng Zheng
Xue-Ling Qi
P2860cites workSynphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusionsQ22009563
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson diseaseQ24291767
Molecular subgroups of medulloblastoma: the current consensusQ24615271
Subgroup-specific structural variation across 1,000 medulloblastoma genomesQ28271811
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcomeQ28298987
Medulloblastoma exosome proteomics yield functional roles for extracellular vesiclesQ28481626
A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma CellsQ28551285
Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expressionQ28598223
Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumorQ33211941
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological featuresQ33366431
Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphomaQ33740695
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasQ34167499
Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomasQ34202479
Reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy and autologous stem cell rescue for children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermal tumorQ34316845
Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancerQ35158541
Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomasQ35194198
Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR signalingQ35587662
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samplesQ35837393
Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.Q35877637
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroupsQ36460209
Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease RecurrenceQ36712351
Genetic grouping of medulloblastomas by representative markers in pathologic diagnosisQ36865020
Medulloblastoma comprises four distinct molecular variantsQ36920479
Signaling pathway and molecular subgroups of medulloblastomaQ36956174
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Q36983860
Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma.Q37256791
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisQ37636027
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.Q38374250
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryQ38829244
ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for PatientsQ38879941
Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.Q38940977
Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumorQ39334547
Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinomaQ40193200
Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumorsQ40347013
Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic diseaseQ40781851
ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patientsQ41333109
Festination Correlates with SNCA Polymorphism in Chinese Patients with Parkinson's Disease.Q42188620
Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer modelsQ43096504
The whole-genome landscape of medulloblastoma subtypesQ46567834
Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.Q48162943
Histones facilitate α-synuclein aggregation during neuronal apoptosisQ48386650
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.Q55469539
alpha-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation.Q55476143
P433issue4
P921main subjectbiomarkerQ864574
tumor invasionQ60750433
P304page(s)1263-1275
P577publication date2018-02-20
P1433published inCancer ScienceQ326125
P1476titleSNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis
P478volume109